If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I think today’s coverage will silence the critics. It goes to show that as its own entity, with its own board and its own vision, a spin out pharma has the potential to do way more, and way better, than it ever would as part of open orphan. I remember the day that we had the big drop on the first spin out RNS and some people scoffing at this just because it wasn’t DIM. Yet already this feels really exciting and I plan to buy a few shares at IPO.
I really like the sound of Jeremy Skillington, he’s got quite the CV. From the website, the vision is clear:
“Poolbeg is led by a team with proven capabilities in identifying, acquiring and accelerating assets through development to commercialisation.”
This isn’t a POLB001 one trick pony, they plan to acquire (which CF is a specialist at)and/or develop a range of promising treatments. I wouldn’t be surprised if they already have their eye on a few treatments that the IPO money could allow them to buy and develop. Could be huge.
Poolbeg looking very exciting. I understand CF doesn't want to label it as a potential Covid drug, but its already sounding not entirely dissimilar to the SNG drug (not invested), although the SNG drug being trialled is nebuliser based. I think this type of drug may have other possibilities beyond flu and Covid if its immune based (as if that's not enough!). Severe asthma and RSV being two that have few treatment options, even here in the UK. Really great stuff.
this is looking really good. well planned coverage and new CEO who really knows what he's doing. exciting times!
this is just the start of the road show for the next two weeks.
Thanks Bazzman for the link. I can’t read the full article unfortunately and it’s not in my hard copy of the Times, but its good to see Poolberg getting promoted in the mainstream press.
Wow, nice coverage.
https://www.thetimes.co.uk/article/our-flu-drug-is-not-to-be-sniffed-at-says-poolbeg-pharma-chief-jeremy-skillington-0dvllns6b
Looking good, GLA
BUSINESS | INTERVIEW
Our flu drug is not to be sniffed at, says Poolbeg Pharma chief Jeremy SkillingtonJeremy Skillington is tackling life-threatening influenza at stock market-bound spin-out Poolbeg Pharma
Jeremy Skillington wants to develop a “conveyor belt of therapies” after focusing on influenza
JASON CLARKE
Brian Carey
Sunday June 20 2021, 12.01am, The Sunday Times